2,696 reports of this reaction
2.9% of all RISANKIZUMAB RZAA reports
#5 most reported adverse reaction
ARTHRALGIA is the #5 most commonly reported adverse reaction for RISANKIZUMAB RZAA, manufactured by AbbVie Inc.. There are 2,696 FDA adverse event reports linking RISANKIZUMAB RZAA to ARTHRALGIA. This represents approximately 2.9% of all 92,878 adverse event reports for this drug.
RISANKIZUMAB RZAA has an overall safety score of 78 out of 100. Patients taking RISANKIZUMAB RZAA who experience arthralgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ARTHRALGIA is a less commonly reported adverse event for RISANKIZUMAB RZAA, but still significant enough to appear in the safety profile.
In addition to arthralgia, the following adverse reactions have been reported for RISANKIZUMAB RZAA:
The following drugs have also been linked to arthralgia in FDA adverse event reports:
ARTHRALGIA has been reported as an adverse event in 2,696 FDA reports for RISANKIZUMAB RZAA. This does not prove causation, but indicates an association observed in post-market surveillance data.
ARTHRALGIA accounts for approximately 2.9% of all adverse event reports for RISANKIZUMAB RZAA, making it a notable side effect.
If you experience arthralgia while taking RISANKIZUMAB RZAA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.